Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19

Anticov. COVID-19_HopitalSaintJosephDRC
Foto: Kenny Mbala / DNDi
24/11/2020 - 30/5/2022
Drugs for Neglected Diseases initiative (DNDi)
German Federal Ministry of Education and Research (BMBF) through a credit for reconstruction (KfW) and the global health agency Unitaid, as part of ACT-A

The aim of the ANTICOV clinical trial is to respond to the urgent need to identify treatments that can be used in the early treatment of mild to moderate cases of COVID-19 to prevent hospitalisation surges that could overwhelm fragile and overburdened health systems in Africa.

The clinical trial will be carried out at 19 sites in 13 African countries by the ANTICOV consortium, which includes 26 African organisations and well-known international research and development institutions, including ISGlobal. The project is being coordinated by the Drugs for Neglected Diseases initiative.

ANTICOV will assess the safety and efficacy of different treatments in 2000 to 3000 patients with mild to moderate disease who have not been hospitalised. Trials will take place in Burkina Faso, Cameroon, Côte d’Ivoire, Ethiopia, Ghana, Guinea, Equatorial Guinea, Kenya, Mali, Mozambique, the Democratic Republic of Congo (DRC), Sudan and Uganda. The aim is to ascertain whether early treatment can prevent progression of COVID-19 to severe disease and potentially limit transmission.

ISGlobal’s role in the ANTICOV project is twofold. First, the Institute will work together with two of the hospitals where clinical trials are being carried out, both located in Mozambique: the Manhiça Health Research Centre (CISM) and the Centro de Investigação e Treino em Saúde da Polana Caniço (CISPOC), which forms part of the country’s National Institute of Health.

In addition, ISGlobal is co-leader, together with the Institute of Tropical Medicine (ITM) in Antwerp (Belgium), of one of the project’s two ancillary studies. This is an immunology study that will be carried out in 7 countries to analyse whether the treatments tested in the clinical trial in patients with mild to moderate COVID-19 alter the strength or duration of immune responses to SARS-CoV-2. The researchers will study antibodies and T-lymphocytes and compare the immune responses of symptomatic and asymptomatic patients

Nuestro equipo


  • Denise Suzanne Naniche
    Denise Suzanne Naniche

Co-PI and Technical coordinator

Scientific Leader of the IMMUNO study and Co-PI of the IMMUNO Study


Otros proyectos

Ver proyectos pasados


Integrating and decentralizing diabetes and hypertension services in Africa


Combatiendo la Resistencia Bacteriana en Europa


Combatting Bacterial Resistance in Europe - Carbapenem Resistance


Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique


Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals


Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique


Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.


Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo

AMR DetecTool

A breakthrough device for the rapid detection of antimicrobial resistance


Hepatitis B Virus COMmunity Screening and Vaccination in Africans


Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV

Hep C Free Baleares

Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.


Close the Gap, Increase Access, Provide Adequate Therapy